Tadalafil/Finasteride

Tier C — Watch / trade

Veru Inc

Originator

2021

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：PDE5A, SRD5A

Brand：Entadfi, ENTADFI, TADFIN

Indications (approved)：Benign prostatic hyperplasia

Regional status

Withdrawn

China

Approved

2025-12-16

Japan

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Tadalafil/Finasteride?

Approved indications include: Benign prostatic hyperplasia.

When does the Tadalafil/Finasteride patent expire?

No public expiry year is available for Tadalafil/Finasteride yet; this page updates once verified.

How do I get a quote for Tadalafil/Finasteride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27